Literature DB >> 27591925

Patients' perspectives on newborn screening for later-onset lysosomal storage diseases.

Emily C Lisi1, Scott Gillespie2, Dawn Laney3, Nadia Ali4.   

Abstract

Lysosomal storage diseases (LSDs) are an individually rare but collectively common group of hereditary, progressive, multi-systemic disorders. Recent technological advances have brought newborn screening (NBS) for LSDs to attention in the United States. However, many LSD symptoms present in later childhood or adulthood, with a wide spectrum of severity. Because late-onset symptoms stray from the traditional NBS model, healthcare providers have expressed concerns about potential harm to patients and/or their families. In this study, 47 individuals with Fabry disease (FD), 22 with Gaucher disease (GD), and 22 with late-onset Pompe disease (LOPD) were surveyed regarding how their life might have been impacted by NBS. Of the 91 participants, none had symptoms at birth and 42 (46.7%) were symptom-free until adulthood. Over half (52.8%) were diagnosed ≥5years from symptom onset; of these, significantly more had FD (60%) or LOPD (63.6%) than GD (23.8%). However, length of diagnostic odyssey was not significantly correlated with opinion on NBS. Most participants either strongly agreed (45%) or agreed (33.3%) with NBS for their condition, with no significant differences between diseases. Opinions on NBS were correlated with participants' opinions on whether NBS would have resulted in better current health, but uncorrelated with disease severity or current life satisfaction. Significantly more participants with FD (42.6%) and LOPD (63.6%) than GD (13.6%) felt they would have greater life satisfaction had they been diagnosed as a newborn (p=0.007). Almost half (41%) of participants would have made different life decisions, including lifestyle, financial, and reproductive decisions. Regarding potential harm, participants were most concerned about insurability and least concerned about removal of children's autonomy. In conclusion, NBS is highly approved of among individuals with LSDs themselves, as it would significantly eliminate diagnostic odysseys and potentially alter life planning.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lysosomal storage diseases; Newborn screening; Patient opinions; Patient perspectives

Mesh:

Year:  2016        PMID: 27591925     DOI: 10.1016/j.ymgme.2016.07.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  Newborn screening for Pompe disease: impact on families.

Authors:  B Pruniski; E Lisi; N Ali
Journal:  J Inherit Metab Dis       Date:  2018-03-28       Impact factor: 4.982

2.  Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021.

Authors:  Cassiano Augusto Braga Silva; Luis Gustavo Modelli de Andrade; Maria Helena Vaisbich; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

3.  Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications.

Authors:  Gé-Ann Kuiper; Olga L M Meijer; Eveline J Langereis; Frits A Wijburg
Journal:  Orphanet J Rare Dis       Date:  2018-01-08       Impact factor: 4.123

4.  A New Approach to Objectively Evaluate Inherited Metabolic Diseases for Inclusion on Newborn Screening Programmes.

Authors:  Alberto Burlina; Simon A Jones; Anupam Chakrapani; Heather J Church; Simon Heales; Teresa H Y Wu; Georgina Morton; Patricia Roberts; Erica F Sluys; David Cheillan
Journal:  Int J Neonatal Screen       Date:  2022-03-25

5.  A Qualitative Study: Mothers' Experiences of Their Child's Late-Onset Pompe Disease Diagnosis Following Newborn Screening.

Authors:  Kaylee Crossen; Lisa Berry; Melanie F Myers; Nancy Leslie; Cecilia Goueli
Journal:  Int J Neonatal Screen       Date:  2022-07-19

Review 6.  Recommendations for patient screening in ultra-rare inherited metabolic diseases: what have we learned from Niemann-Pick disease type C?

Authors:  María-Jesús Sobrido; Peter Bauer; Tom de Koning; Thomas Klopstock; Yann Nadjar; Marc C Patterson; Matthis Synofzik; Chris J Hendriksz
Journal:  Orphanet J Rare Dis       Date:  2019-01-21       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.